{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:16:30Z","timestamp":1783048590943,"version":"3.54.6"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82560044"],"award-info":[{"award-number":["82560044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360029"],"award-info":[{"award-number":["82360029"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009620","name":"Gansu Province Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018554","name":"Science and Technology Program of Gansu Province","doi-asserted-by":"publisher","award":["21JR11RA104"],"award-info":[{"award-number":["21JR11RA104"]}],"id":[{"id":"10.13039\/501100018554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018554","name":"Science and Technology Program of Gansu Province","doi-asserted-by":"publisher","award":["21JR7RA435"],"award-info":[{"award-number":["21JR7RA435"]}],"id":[{"id":"10.13039\/501100018554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018554","name":"Science and Technology Program of Gansu Province","doi-asserted-by":"publisher","award":["21JR7RA394"],"award-info":[{"award-number":["21JR7RA394"]}],"id":[{"id":"10.13039\/501100018554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.leukres.2026.108249","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:19:13Z","timestamp":1778577553000},"page":"108249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical and immune features associated with chromosome 13q deletion and PRKCSH downregulation in newly diagnosed multiple myeloma"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3837-6342","authenticated-orcid":false,"given":"Jiayuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuxi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.leukres.2026.108249_bib1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108249_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garcia-Ortiz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.leukres.2026.108249_bib3","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2025018945","article-title":"Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial","author":"Jin","year":"2026","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.leukres.2026.108249_bib4","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/S2352-3026(25)00143-7","volume":"12","author":"Mateos","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2026.108249_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(25)00653-9","article-title":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial","author":"Einsele","year":"2026","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2026.108249_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105514","article-title":"A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients","volume":"10","author":"Martino","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.leukres.2026.108249_bib7","article-title":"The efficacy and safety of anti-CD38 monoclonal antibodies in transplant-ineligible newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials","volume":"74","author":"Aliyeva","year":"2025","journal-title":"Curr. Res. Transl. Med."},{"key":"10.1016\/j.leukres.2026.108249_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108007","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma","volume":"232","author":"Choi","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.leukres.2026.108249_bib9","article-title":"A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma","author":"Rade","year":"2025","journal-title":"Cancer Cell"},{"issue":"27","key":"10.1016\/j.leukres.2026.108249_bib10","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108249_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153723","article-title":"Cancer immunotherapy: challenges and limitations","volume":"229","author":"Taefehshokr","year":"2022","journal-title":"Pathol. Res. Pract."},{"issue":"6","key":"10.1016\/j.leukres.2026.108249_bib12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.leu.2402125","article-title":"Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy","volume":"15","author":"Fonseca","year":"2001","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.leukres.2026.108249_bib13","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2026.108249_bib14","first-page":"2663","article-title":"Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China","volume":"125","author":"Lai","year":"2012","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"2","key":"10.1016\/j.leukres.2026.108249_bib15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.leukres.2026.108249_bib16","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.trecan.2020.05.006","article-title":"Genomic instability in multiple myeloma","volume":"6","author":"Alagpulinsa","year":"2020","journal-title":"Trends Cancer"},{"issue":"11","key":"10.1016\/j.leukres.2026.108249_bib17","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood.V86.11.4250.bloodjournal86114250","article-title":"Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities","volume":"86","author":"Tricot","year":"1995","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2026.108249_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1034\/j.1600-0609.2003.00111.x","article-title":"Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma","volume":"71","author":"Kaufmann","year":"2003","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108249_bib19","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/10428194.2011.634042","article-title":"Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial","volume":"53","author":"Nemec","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"10","key":"10.1016\/j.leukres.2026.108249_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108249_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155828","article-title":"Interleukin-8: an evolving chemokine","volume":"153","author":"Matsushima","year":"2022","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.leukres.2026.108249_bib22","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/mt.2012.127","article-title":"Inducible IL10(+) suppressor B cells inhibit CNS inflammation and T helper 17 polarization","volume":"20","author":"Hsieh","year":"2012","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.leukres.2026.108249_bib23","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1172\/JCI78891","article-title":"Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs","volume":"124","author":"Akdis","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"Pt A","key":"10.1016\/j.leukres.2026.108249_bib24","article-title":"Interleukin-10 increases macrophage-mediated chemotherapy resistance via FABP5 signaling in multiple myeloma","volume":"124","author":"Zhang","year":"2023","journal-title":"Int Immunopharmacol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108249_bib25","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.immuni.2014.03.012","article-title":"Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis","volume":"40","author":"Zigmond","year":"2014","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.leukres.2026.108249_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09167","article-title":"Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production","volume":"8","author":"Uhl","year":"2022","journal-title":"Heliyon"},{"issue":"6535","key":"10.1016\/j.leukres.2026.108249_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc8433","article-title":"Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10","volume":"371","author":"Saxton","year":"2021","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.leukres.2026.108249_bib28","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1158\/0008-5472.CAN-14-3016","article-title":"IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells","volume":"75","author":"Sun","year":"2015","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.leukres.2026.108249_bib29","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1091\/mbc.e09-04-0316","article-title":"Glucosidase II beta subunit modulates N-glycan trimming in fission yeasts and mammals","volume":"20","author":"Stigliano","year":"2009","journal-title":"Mol. Biol. Cell"},{"issue":"10","key":"10.1016\/j.leukres.2026.108249_bib30","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/glycob\/cwp104","article-title":"Sugar-binding activity of the MRH domain in the ER alpha-glucosidase II beta subunit is important for efficient glucose trimming","volume":"19","author":"Hu","year":"2009","journal-title":"Glycobiology"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:25:53Z","timestamp":1783045553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"alternative-id":["S0145212626000937"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108249","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and immune features associated with chromosome 13q deletion and PRKCSH downregulation in newly diagnosed multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108249"}}